Amylin Pharmaceuticals Inc.
Product: AC137 amylin analog
Indication: Type 1 juvenile onset diabetes
Phase II data presented at the American Diabetes Association showed that at 14 days, the 21 patients in the placebo group had post-meal glucose (mean of changes in AUC) of +229.
The 15 patients in the 30 µg group had post-meal glucose of
-6,645 mg/dl (p=0.02) and tripro-amylin plasma peaks of